MORGAN STANLEY PLC/CALL/AMGEN/320/0.1/17.01.25 | Market Closed - Börse Stuttgart 19:36:28 12/06/2024 BST | ||
| 1.93 EUR | -3.98% |
|
| Current month | -11.45% | ||
| 1 month | -22.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 12/06/24 | 1.93 | -3.98% |
| 11/06/24 | 2.01 | -2.43% |
| 10/06/24 | 2.06 | -8.04% |
| 07/06/24 | 2.24 | -2.61% |
| 06/06/24 | 2.3 | -5.74% |
Delayed Quote Börse Stuttgart
Last update June 12, 2024 at 07:36 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MB0BQE |
| ISIN | DE000MB0BQE8 |
| Date issued | 09/11/2022 |
| Strike | 320 $ |
| Maturity | 17/01/2025 (219 Days) |
| Parity | 10 : 1 |
| Emission price | 3.94 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.04 € |
|---|---|
| Lowest since issue | 0.37 € |
| Spread | 0.03 € |
| Spread % | 1.52% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
300.7
USD
Average target price
316.3
USD
Spread / Average Target
+5.18%
- Stock Market
- Warrants
- Warrant